Overview

Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration

Status:
Completed

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

The present study will be conducted in order to compare the bioavailability of the generic Test product (Deferiprone 500 Lipomed tablets, Lipomed AG, Switzerland) with a marketed Reference product (Ferriprox® film-coated tablets, Apotex Europe B.V., Germany) both containing 500 mg deferiprone. For this issue the pharmacokinetics will be characterised after single dose administration of each one tablet.

Phase:

Phase 1

Details

Lead Sponsor:

SocraTec R&D GmbH

Collaborator:

SocraMetrics GmbH

Treatments:

Deferiprone